KAI1 Antibody
| Code | Size | Price |
|---|
| PSI-4073-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4073-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
KAI1 Antibody: R2, 4F9, C33, IA4, ST6, GR15, KAI1, SAR2, TSPAN27, CD82 antigen, C33 antigen, Tspan-27
Application Note:
KAI1 antibody can be used for detection of KAI1 by Western blot at 0.5 - 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
KAI1 Antibody: KAI1 was initially identified from a T-cell activation study as a four-transmembrane protein that plays an accessory role in T-cell activation, and was later determined to act as a cancer metastasis suppressor gene. This protein is ubiquitously expressed at moderate to high levels in most tissues, but its expression is downregulated during tumor progression. The loss of KAI1 and p53 is associated with poor survival for prostate and other cancer patients. Recently, KAI1 was found to interact with DARC, the Duffy antigen for chemokines using a yeast two hybrid screen. It is thought that tumor cells dislodged from the primary tumor and expressing KAI1 interact with DARC proteins expressed on vascular cells, transmitting a senescent signal to the tumor cells, while tumor cells that have lost KAI1 expression can proliferate and potentially give rise to metastases. At least two isoforms of KAI1 are known to exist.
Background References:
- HW Gaugitsch, Hofer E, Huber NE, et al. A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen SM23. Eur. J. Immunol.1991; 21:377-83.
- Gil ML, Vita N, Lebel-Binay S, et al. A member of the tetra spans transmembrane protein superfamily is recognized by a monoclonal antibody raised against an HLA class I-deficient, lymphokine-activated killer-susceptible, B lymphocyte line. Cloning and functional studies. J. Immunol.1992; 2826-33.
- Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science1995; 884-86.
- Kauffman EC, Robinson VL, Stadler WM, et al. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol.2003; 169:1122-33.
Buffer:
KAI1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
KAI1 antibody was raised against a 15 amino acid synthetic peptide from near the carboxy terminus of human KAI1.
The immunogen is located within the last 50 amino acids of KAI1.
The immunogen is located within the last 50 amino acids of KAI1.
NCBI Gene ID #:
3732
NCBI Official Name:
CD82 molecule
NCBI Official Symbol:
CD82
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_002222
Protein GI Number:
4504813
Purification:
KAI1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
Swissprot #:
P27701
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | KAI1 Peptide | PSI-4073P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|